- POSITIVE
Quarterly Revenue Foghorn Therapeutics Inc Jun-2026 Quarterly Revenue is $16 Million which is growth of 112.7% YoY.
- POSITIVE
Quarterly Net Profit Foghorn Therapeutics Inc Jun-2026 Quarterly Net Profit is $-7 Million which is growth of 59.9% YoY.
2.090.12(6.09%)
914.8K
XNAS Volume
High vol.+loss this week
XNAS 07 Oct, 2026 5:30 PM (EDT)
Foghorn Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents
Forecaster Analyst Estimates for Foghorn Therapeutics Inc share price target, revenues, EPS, net income and more
Foghorn Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Rev. | 16.1 | 3.3 | 9.3 | 8.2 | 7.6 | 6 | 2.9 | 7.8 | 6.9 | 5.1 | 5.8 | 17.5 | 5.6 | |
Cost Of Rev. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| 24.9 | 24.8 | 28.8 | 26.7 | 28.7 | 28.9 | 26.9 | 31.7 | 31.1 | 33.2 | 31.2 | 34.6 | 37.7 | ||
Operating Profit | -8.8 | -21.6 | -19.6 | -18.5 | -21.1 | -22.9 | -24 | -23.9 | -24.2 | -28.2 | -25.5 | -17.1 | -32.1 | |
| 1.6 | 1.7 | 1.7 | 2 | 2.3 | 2.7 | 3.1 | 3.5 | 2.9 | 2.4 | 2.7 | 2.8 | 2.8 | ||
Profit Before Tax | -7.2 | -19.9 | -21.7 | -15.9 | -17.9 | -18.8 | -19.5 | -19.1 | -23 | -25 | -22.1 | -13.6 | -28.5 | |
Tax | - | - | - | - | - | - | 2 | 0.7 | 0.9 | |||||
| -7.2 | -19.9 | -21.7 | -15.9 | -17.9 | -18.8 | -19.5 | -19.1 | -23 | -25 | -24.1 | -14.4 | -29.5 | ||
Diluted NI Avail to Com Stockholders Ann. | -7.2 | -19.9 | -21.7 | -15.9 | -17.9 | -18.8 | -19.5 | -19.1 | -23 | -25 | -24.1 | -14.4 | -29.5 | |
Basic EPS | -0.1 | -0.3 | -0.3 | -0.3 | -0.3 | -0.3 | -0.3 | -0.3 | -0.5 | -0.6 | -0.6 | -0.3 | -0.7 | |
Diluted EPS After ExtraOrdinary | -0.1 | -0.3 | -0.3 | -0.3 | -0.3 | -0.3 | -0.3 | -0.3 | -0.4 | -0.6 | -0.6 | -0.3 | -0.7 | |
Number Of Shares End | 70.6 | 69.5 | 63.1 | 63 | 63 | 62.9 | 62.9 | 62.6 | 51.6 | 42.4 | 42.2 | 42 | 41.8 | |
Net Income Continuing Discontinued Operations | -7.2 | -19.9 | -21.7 | -15.9 | -17.9 | -18.8 | -19.5 | -19.1 | -23 | -25 | -24.1 | -14.4 | -29.5 | |
Normalized Income | -7.2 | -19.9 | -17.4 | -15.9 | -17.9 | -18.8 | -19.5 | -19.1 | -20.6 | -25 | -24.1 | -14.4 | -29.5 | |
Interest Income | 1.6 | 1.7 | 1.7 | 2 | 2.3 | 2.7 | 3.1 | 3.5 | 2.9 | 2.4 | 2.7 | 2.8 | 2.8 | |
Interest | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Net Interest Income | 1.6 | 1.7 | 1.7 | 2 | 2.3 | 2.7 | 3.1 | 3.5 | 2.9 | 2.4 | 2.7 | 2.8 | 2.8 | |
EBIT | -8.8 | -21.6 | -19.6 | -18.5 | -21.1 | -22.9 | -24 | -23.9 | -24.2 | -28.2 | -25.5 | -17.1 | -32.1 | |
EBITDA | -8.6 | -21.3 | -18.8 | -17.7 | -20.3 | -22.1 | -23.2 | -23.1 | -23.4 | -27.4 | -24.6 | -16.2 | -31.2 | |
Reconciled Cost Of Rev. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Reconciled Depr. | 0.2 | 0.2 | 0.8 | 0.9 | 0.9 | 0.8 | 0.8 | 0.7 | 0.8 | 0.8 | 0.9 | 0.9 | 0.9 | |
Profit From Continuing Operations | -7.2 | -19.9 | -21.7 | -15.9 | -17.9 | -18.8 | -19.5 | -19.1 | -23 | -25 | -24.1 | -14.4 | -29.5 | |
Normalized EBITDA | -8.6 | -21.3 | -14.5 | -17.7 | -20.3 | -22.1 | -23.2 | -23.1 | -21.1 | -27.4 | -24.6 | -16.2 | -31.2 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Foghorn Therapeutics Inc competitor comparison and performance snapshot within industry
Foghorn Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Annual Revenue Foghorn Therapeutics Inc Dec-2025 Annual Revenue is $31 Million which is growth of 36.8% YoY.
- POSITIVE
Annual Net Profit Foghorn Therapeutics Inc Dec-2025 Annual Net Profit is $-74 Million which is growth of 14.2% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | TTM | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
17.2% | 138.6% | 30.9 | 22.6 | 34.2 | 19.2 | 1.3 | 0.4 | |||||
Cost Of Rev. Ann. | - | - | - | - | - | - | - | - | - | - | ||
Gross Profit Ann. | - | - | - | - | - | - | - | - | - | - | ||
Operating Exp. Ann. | -6.1% | 10.4% | 105.2 | 113 | 122.9 | 142.1 | 136.4 | 102.1 | 69 | 51.1 | 26.1 | |
Operating Profit Ann. | - | - | -68.5 | -82.1 | -100.3 | -107.9 | -117.1 | -100.7 | -68.5 | -51.1 | -26.1 | |
15.1% | - | 7.1 | 8.7 | 11.9 | 10.9 | 5.7 | 0.7 | 0 | -0 | -0.3 | ||
Other Exp. Ann. | - | - | -0.9 | 1.8 | 2.8 | 2.6 | -1.2 | -0.3 | -0 | |||
PBT Ann. | - | - | -64.6 | -74.3 | -86.6 | -94.2 | -108.9 | -101.3 | -68.8 | -51.1 | -26.3 | |
Tax Ann. | - | - | - | 4.2 | - | - | - | - | - | |||
- | - | -64.6 | -74.3 | -86.6 | -98.4 | -108.9 | -101.3 | -68.8 | -51.1 | -26.3 | ||
Diluted NI Avail to Com Stockholders Ann. | - | - | -64.6 | -74.3 | -86.6 | -98.4 | -108.9 | -101.3 | -68.8 | -51.1 | -26.3 | |
EPS Ann. | - | - | -1.2 | -1.6 | -2.3 | -2.6 | -2.7 | -6.2 | -2.6 | -1.3 | ||
Diluted EPS Ann. | - | - | -1.2 | -1.6 | -2.3 | -2.6 | -2.7 | -6.2 | -2.6 | -1.3 | ||
Number Of Shares End | 14.7% | 11.4% | 63.1 | 62.9 | 42.2 | 41.8 | 38.1 | 36.8 | 22.1 | - | ||
Total Exp. Ann. | -6.1% | 10.4% | 113 | 122.9 | 142.1 | 136.4 | 102.1 | 69 | 51.1 | 26.1 | ||
Net Income Continuing Discontinued Operations Ann. | - | - | -64.6 | -74.3 | -86.6 | -98.4 | -108.9 | -101.3 | -68.8 | -51.1 | -26.3 | |
Normalized Income Ann. | - | - | -60.3 | -70 | -84.2 | -98.4 | -108.9 | -100.1 | -68.5 | -51.1 | -26.3 | |
Interest Income Ann. | 15.1% | 54.1% | 7.1 | 8.7 | 11.9 | 10.9 | 5.7 | 2.6 | 1 | 0.5 | 0.1 | |
Interest Ann. | - | - | - | - | - | 1.9 | 1 | 0.5 | 0.4 | |||
EBITDA Ann. | - | - | -66.4 | -78.8 | -97.2 | -104.5 | -105.6 | -96.2 | -66.5 | -49.9 | -25.6 | |
Reconciled Cost Of Rev. Ann. | - | - | - | - | - | - | - | - | - | - | ||
Reconciled Depr. Ann. | 0% | 20.5% | 2.1 | 3.3 | 3.1 | 3.5 | 3.3 | 3.2 | 1.3 | 0.7 | 0.4 | |
Profit From Continuing Operations Ann. | - | - | -64.6 | -74.3 | -86.6 | -98.4 | -108.9 | -101.3 | -68.8 | -51.1 | -26.3 | |
Normalized EBITDA Ann. | - | - | -62.1 | -74.5 | -94.8 | -104.5 | -105.6 | -95 | -66.2 | -49.9 | -25.6 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
36.7%
2Y CAGR
-4.9%
3Y CAGR
17.2%
5Y CAGR
138.6%
Total Revenue Annual growth is stable compared to historical averages.
Operating Exp. Ann.
1Y CHG
-8.1%
2Y CAGR
-10.8%
3Y CAGR
-6.1%
5Y CAGR
10.4%
7Y CAGR
23.3%
Operating Expenses Annual Cr is falling faster than historical averages.
Foghorn Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Total Shareholders Fund Foghorn Therapeutics Inc Dec-2025 Total Shareholders Fund is $-108 Million which is growth of -138.3% YoY.
- NEGATIVE
Total Assets Foghorn Therapeutics Inc Dec-2025 Total Assets is $198 Million which is growth of -30.2% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 |
|---|---|---|---|---|---|---|---|---|---|---|---|
-21.2% | -5% | 198.1 | 284 | 285.9 | 404.9 | 519.8 | 255.6 | 22.3 | 43.1 | ||
-8.8% | 22.9% | 306.6 | 329.5 | 363.1 | 404.8 | 422.9 | 109.4 | 110.4 | 82.3 | ||
- | - | -108.5 | -45.5 | -77.2 | 0.1 | 96.9 | 146.2 | -88 | -39.3 | ||
Total Capitalization Ann. | - | - | -108.5 | -45.5 | -77.2 | 0.1 | 96.9 | 165.8 | -77.1 | -32.2 | |
Tangible Assets Ann. | - | - | -108.5 | -45.5 | -77.2 | 0.1 | 96.9 | 146.2 | -88 | -39.3 | |
Working Capital Ann. | -29.6% | -9.6% | 103.5 | 182.6 | 181.7 | 296.2 | 410.9 | 171.8 | 4.2 | 36.9 | |
Invested Capital Ann. | - | - | -108.5 | -45.5 | -77.2 | 0.1 | 96.9 | 165.8 | -72.9 | -32.2 | |
Tangible Book Value Ann. | - | - | -108.5 | -45.5 | -77.2 | 0.1 | 96.9 | 146.2 | -88 | -39.3 | |
Borrowings Ann. | -7.1% | -12.8% | 41.3 | 37.1 | 45.1 | 51.5 | 58.3 | 82 | 16.6 | 7 | |
Net Debt Ann. | - | - | - | - | - | - | - | - | 0.1 | - | |
Share Issued Ann. | 10.7% | 9% | 56.7 | 55.6 | 42.3 | 41.8 | 41.3 | 36.8 | 35.7 | 35.7 | |
Number Of Shares End | 14.7% | 11.4% | 63.1 | 62.9 | 42.2 | 41.8 | 38.1 | 36.8 | 22.1 | - |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
-30.2%
2Y CAGR
-16.8%
3Y CAGR
-21.2%
5Y CAGR
-5%
7Y CAGR
24.3%
Total Assets Annual is falling faster than historical averages.
Total Current Liabilities Ann.
1Y CHG
-10.9%
2Y CAGR
1.1%
3Y CAGR
2.6%
5Y CAGR
25.9%
7Y CAGR
50%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Foghorn Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Book Value Per Share Foghorn Therapeutics Inc Book Value Per Share is $-1 which is growth of -0.6% YoY.
- NEUTRAL
ROE Foghorn Therapeutics Inc ROE is 0% which is growth of 0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 |
|---|---|---|---|---|---|---|---|---|---|---|---|
RoA Ann. % | - | - | - | -30.40% | -28.50% | -23.55% | -26.13% | -49.51% | -156.36% | -61.17% | |
ROE Ann. % | - | - | - | - | - | -224.54% | -83.37% | -236.54% | - | - | |
ROIC % | - | - | - | - | - | -45.4 | -18.6 | -25.3 | - | - | |
OPM Ann. % | - | - | -265.64% | -443.70% | -315.93% | -609.20% | -7,637.15% | -15,937.44% | - | - | |
Inventory Turnover Ratio Ann. | - | - | - | - | - | - | - | - | - | - | |
Asset Turnover Ann. % | - | - | - | 0.1 | 0.1 | 0 | - | - | |||
Working Capital Turnover Ann. | 44.2% | - | 0.3 | 0.1 | 0.2 | 0.1 | |||||
Quick Ratio Ann. | - | - | - | 3.6 | 4 | 6.3 | 9.3 | 9.9 | 1.2 | 11.6 | |
Current Ratio Ann. | - | - | - | 3.7 | 4.1 | 6.4 | 9.4 | 10.1 | 1.3 | 11.7 | |
Interest Coverage Ratio Ann. | - | - | - | - | - | - | -52.2 | -69.3 | -93.7 | -70 | |
LT Debt To Equity Ann. | - | - | - | - | - | 406.6 | 0.5 | 0.5 | - | - |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Foghorn Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Cash From Operating Activity Foghorn Therapeutics Inc Dec-2025 Cash From Operating Activity is $-86 Million which is growth of 14.2% YoY.
- POSITIVE
Net Cash Flow Foghorn Therapeutics Inc Dec-2025 Net Cash Flow is $27 Million which is growth of 208.4% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 |
|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | -86.1 | -100.4 | -118.1 | 193.6 | -50.3 | -31.3 | -46.3 | -22.7 | ||
- | - | 112 | -29.9 | 144.5 | -244.3 | 36.2 | -108.9 | -1 | -1.5 | ||
-17.8% | -65.9% | 1 | 105.4 | 1.8 | 1.8 | 22.4 | 217.5 | 24 | 51.8 | ||
Cash Plus Cash Eqv. End Of Year Ann. | 16% | -2.3% | 84.1 | 57.2 | 82 | 53.9 | 102.9 | 94.5 | 17.3 | 40.6 | |
Net Increase In Cash Plus Cash Eqv.s Ann. | - | -19% | 27 | -24.9 | 28.1 | -49 | 8.3 | 77.3 | -23.3 | 27.6 | |
Cash Plus Cash Eqv. Begin Of Year Ann. | -17.8% | 27% | 57.2 | 82 | 53.9 | 102.9 | 94.5 | 17.3 | 40.6 | 13 | |
Income Tax Paid Supplemental Data Ann. | - | - | 0 | 0.9 | 3.6 | - | - | - | - | - | |
Interest Paid Supplemental Data Ann. | - | - | - | - | - | 1.7 | 0.7 | 0.4 | 0.2 | ||
Capex Ann. | - | - | -0.1 | -0.9 | -1.2 | -1.2 | -3.3 | -16.2 | -1 | -1.5 | |
Issuance Of Capital Stock Ann. | - | -70.2% | 0.5 | 103.4 | - | 42.2 | 212 | 15.3 | 40.4 | ||
Issuance Of Debt Ann. | - | - | - | - | - | - | 19.8 | 8 | 12 | ||
Repayment Of Debt Ann. | - | - | - | - | - | -21.2 | -15.5 | -0.8 | |||
Repurchase Of Capital Stock Ann. | - | - | - | - | - | - | - | - | - | - | |
Free Cash Flow Ann. | - | - | -86.2 | -101.3 | -119.3 | 192.4 | -53.6 | -47.5 | -47.3 | -24.2 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Investing Act. Ann.
2Y CAGR
-12%
Cash from Investing Activity Annual growth is higher than historical averages.
Cash from Financing Act. Ann.
1Y CHG
-99.1%
2Y CAGR
-25.5%
3Y CAGR
-17.8%
5Y CAGR
-65.9%
7Y CAGR
-43.1%
Cash from Financing Annual Activity is falling faster than historical averages.